Supernus Pharma (SUPN) Tops Q2 EPS by 14c, Revenues Miss; Offers FY18 Revenue Outlook Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Supernus Announces Second Quarter 2018 Financial Results and Record Quarterly Revenue
August 7, 2018 4:16 PM EDTTotal revenue of $99.5 million, a 31% increase over 2017Net product sales of $97.0 million, a 32% increase over 2017Operating earnings of $35.7 million, a 37% increase over 2017Diluted earnings per share (GAAP) of $0.57, a 78% increase over 2017Completed enrollment in the first SPN-812 Phase III trial (P301), with data expected in the fourth quarter of 2018
ROCKVILLE, Md., Aug. 07, 2018 (GLOBE NEWSWIRE) -- Â - Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN), a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today reported record financial results for the second quarter of 2018 and... More
